Sign In
Buy GHRS
$23.61
+1.52 (+6.88%)
At Close: Jun 23, 2026
3 Psychedelic Stocks to Ride to the Moon and Beyond
07:21am, Saturday, 06'th Jul 2024
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
09:55am, Monday, 13'th May 2024
GH Research (GHRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
10:56am, Friday, 10'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 166.9% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the p
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
07:00am, Friday, 03'rd May 2024
DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
10:55am, Tuesday, 05'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, t
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
07:00am, Thursday, 29'th Feb 2024
DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di
Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
11:22am, Tuesday, 16'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 488.7% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, t
GH Research Reports Third Quarter Financial Results and Provides Business Updates
04:45pm, Thursday, 09'th Nov 2023
DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di
New Strong Buy Stocks for October 25th
08:16am, Wednesday, 25'th Oct 2023
RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023.
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
04:45pm, Friday, 29'th Sep 2023
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
07:00am, Wednesday, 23'rd Aug 2023
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di
The 3 Best Psychedelic Stocks to Buy Now
08:00am, Thursday, 29'th Jun 2023
Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedeli
The 7 Most Promising Psychedelic Stocks to Buy in February
02:30pm, Sunday, 05'th Feb 2023
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
Psychedelic Sunday: Competitive Strategies
11:45am, Sunday, 15'th Jan 2023
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
